CTMX Shows Higher ORR Than Temab‑A, Needs Validation
Late line CRC therapies in development following $CTMX's data this week (from Guggenheim). A lot is riding on $CTMX's 10 mg/kg cohort which had just 19 evaluable patients (3 patients were excluded so ITT response rate is lower) so this needs to be corroborated in the dose optimization stage. Temab-A's ORR is probably in the 15-20% range in the broad CRC population (data in the table are for MET amplified CRC), making $CTMX's ORR superior for now.
Largest Review Finds No Evidence Cannabis Relieves Anxiety, Depression, PTSD
No evidence that medicinal cannabis effectively treats anxiety, depression, or PTSD - according to the largest review of cannabinoids ever conducted.
AI's Real Bottleneck: Accelerating Human Processes, Not Tech
Our bottleneck for some of the biggest change ahead may be humans. I shared the story of Paul Conyngham and his dog Rosie on my Instagram when it broke. When I read the coverage, my shock was less that ChatGPT...
Unregulated Online Market Sells Ketamine for Depression Relief
Ketamine, an operating-room anesthetic also prized as the street drug “K” is now at the heart of a largely unregulated online industry offering depression relief. https://t.co/pGd0TO5uFy via @WSJ
World's Largest In‑Vivo CRISPR Data Engine Unveiled
From Prof Jin and my colleagues @scrippsresearch the largest in vivo CRISPR data engine, nearly 8 million cells, in collaboration with @nvidia and featured at GTC
Pfizer's Ibrance Successor Advances with Fresh Study Data
Pfizer’s Ibrance successor moves forward with new study data https://t.co/ozXAZYmc3M by Kristin Jensen $PFE $LLY $NVS $RHHBY $ONC
GLP‑1 Weight Loss Shows No Extra Muscle Loss
A study asserts lack of disproportionate loss of muscle mass or strength cf weight loss from GLP-1 drug treatment, in mice and a small short term (12 weeks) trial in men The issue remains unsettled and counters the efforts by companies...
Trump Pushes Drug Pricing Overhaul Despite Congressional Resistance
The Trump administration is "gearing up for war" to push Congress to codify its drug pricing policy — despite little appetite for it on the Hill. Still, the pharma industry sees risk in the back-and-forth. https://t.co/DR2LotvXFq
Peptide Drugs Require Robust Safety and Efficacy Evidence
In response to suggesting peptide drugs should have good evidence on safety and efficacy in order to weigh the risks and benefit…
R1 Secures $78M to Advance Kidney Drug Development
R1 starts up with $78M, aiming for a better kidney drug https://t.co/PQQjX47ODM by @gwendolynawu #biotecjh #startups
New Drug Could Eradicate Sleeping Sickness, Says NPR
Sleeping sickness could be wiped out with this new drug: my comments @NPR @NPRGlobalHealth https://t.co/T0mAeX8P0A
Judge Stalls Kennedy Childhood Vaccine Overhaul Meeting
Kennedy childhood vaccine overhaul stalled by judge The next meeting of the Advisory Committee on Immunization Practices was scheduled for this week, but has been postponed due to the ruling https://t.co/0cUIXEVgyV
Semaglutide Boosts Metabolism, Reduces Anxiety in Obese Mice
Beyond the Weight Loss: The Effects of Semaglutide on Standard and Diet-Induced Obese Mice 🤔"..semaglutide improved glucose metabolic health inboth diet groups..while chronic semaglutide treatment appeared to exertanxiolytic effects in obese mice, opposit[e] effects were observed in lean animals.." https://t.co/doU6EkwT7z
FDA Urges IRB Overhaul to Match China's 60‑day Trials
FDA commissioner Makary at a CMS conference today in Baltimore calls for “big and different” IRB reforms to catch China's speedy trial starts - pre-IND phase can run 380 days in the US, he said, while China is pushing for...
CytomX Jumps 66% on Promising Colorectal ADC Data
CytomX surges on positive data for ‘masked’ ADC in colorectal cancer https://t.co/PxQMISvyri by @Lilah_Alvarado $CTMX + 66%
Structure's GLP-1 Pill Shows Best-in-Class Obesity Results
Structure’s GLP-1 pill shows ‘best-in-class’ potential in obesity trial https://t.co/j0fzAg6GRV @ByJonGardner $GPCR $LLY $NVO $AZN $MRK #obesity
Multi-Ancestry Polygenic Score Predicts T2D, Obesity, GLP‑1 Need
A polygenic risk score that predicts Type 2 diabetes, obesity, and likelihood for requiring a GLP-1 drug. Across 6 ancestries. https://t.co/5hTVv8kqlK https://t.co/IgXhx8vFA6
Biotech IPOs Falter as Companies Pull Planned Listings
16March: Which companies recently withdrew their planned IPOs? And how much have the stocks of this year's #biotech IPOs risen or fallen this year? Read about the IPO market plus updates on $BNTX, $IXHL, and $INKT in my latest StockWatch...
AI-Driven Digital Biology Delivers Custom Cancer Vaccine for Dog
The era of digital biology, exemplified by making a bespoke and effective vaccine for cancer in a dog, is taking off. Access to the AI-Coscientist. A new feature @NatureMedicine https://t.co/AR9lqne7E1
P > 0.05 Means Inconclusive, Not Proof of No Effect
Correct interpretation of p > 0.05: The current sample size did not yield sufficient evidence to reject, at the incredibly arbitrary 0.05 level, the supposition that the treatment does nothing, assuming data model M (describe M ...) which forgot to...
Sarepta Tests Elevidys Safety, Sana
Sarepta tests new Elevidys safeguards; Sana advances diabetes cell therapy https://t.co/hkixuANCCV $SRPT $SANA $INO $BAYRY #biotech
Psychedelic Medicine Shifts From Stigma to Scientific Momentum
1/6 Excited to join @START_Global this week in Switzerland for a fireside chat on the psychedelic medicine opportunity. As co-founder and former CEO of one of the first psychedelics-focused biotechs, I’ve had a front-row seat to this field’s move from stigma...
Structure's Obesity Pill Shows Phase 2 Weight‑Loss Promise
Pretty impressive data from $gpcr, which remains my favorite ticker. Structure's obesity pill shows weight loss promise in Phase 2 trial https://t.co/T0JU2UuftY
EU Approves Imfinzi‑chemo Combo for Gastric Cancers
#AZN Imfinzi (durvalumab) combined with 'standard-of-care' Chemotherapy has been approved in the EU for treating Adults with forms of Gastric and Gastroesophageal Junction Cancers, following the MATTERHORN Phase III trial.
Cell Painting Images Predict Cellular Age Without Methylation
A model that predicts cellular age from Cell Painting microscopy images alone. No DNA methylation needed. The model captures morphological aging hallmarks across nuclear and cytoplasmic compartments, correlates with chronological age AND epigenetic clocks. The promise: screen for rejuvenation compounds...
Clinical Trials Randomize Experiments, Keep Standard Care for All
The dog *also* got standard-of-care treatment. Who knows what worked? Randomize some getting one-off custom vaccines but whole group gets standard of care. How ALL modern clinical trials work. If true, put big money to improve. Otherwise don’t push snake oil on...
Graph AI Accelerates Longevity Drug Discovery in New Alliance
Solve Aging: Biophytis and LynxKite are expanding their alliance to use graph-based AI to speed discovery of new longevity drugs, aiming to map complex aging biology and surface novel targets for age-related disease. The “AI x longevity” stack is quietly...
Open‑source Hermes Agent for mRNA Vaccine Design
Has anyone built full open source tooling for Hermes Agent @NousResearch for Bioinformatics (mRNA vaccine design is the target)? It'll need new agent skills too. Would you use it if I built it? I have a few hours left to...
AI Beats FDA, Prompting DIY Drug Use
AI's capabilities have outpaced the FDA's capabilities to regulate it There are literal cures that can be designed and synthesized but have no way to reach the market due to regulatory/ethics blocks People will, like with Peptides, start dosing themselves & their...
Low‑Cost Vaccines Fight Pseudoscience, Yet Remain Unaccepted
Please @X I make low cost vaccines to help humanity and debunk pseudoscience. This is unacceptable
GLP‑1 Drugs: Promising yet Unproven Healthspan Extension
GLP-1 drugs for extending healthspan? Intriguing but we're a long way off from evidence Discussed at length in Super Agers as a candidate drug beyond lifestyle + factors @TheEconomist gift link https://t.co/A2dpfcnApF https://t.co/3gY8iACeGs
Variant Bio Hunts Rare Traits For
From a tiny idea in our Lux office to deal after deal... ...@VariantBio finding outlier people, with outlier traits, in outlier parts of the world to make outlier drugs. organ by organ ... https://t.co/I5fK8nzZb4
Approve Longevity Drugs for Disease First, Then Expand to Aging
The only sustainable path to development of longevity therapeutics is to get the potential longevity drug approved for a disease, then go for indication expansion and study it in the context of aging at different doses and regimens. To be...
Deconstructing Psychedelics to Engineer Non‑Hallucinogenic Therapies
How do you break psychedelic molecules into parts, like cars in a chop shop, and build new ones? A look into non-psychedelic psychedelic medicine by Clayton Dalton, an ER doc and Ferriss-UC Berkeley Psychedelic Journalism Fellow @ucbsoj & @SciPsychedelics https://t.co/b7R4aTNdyf
Regulators, Not Pharma, Block Self‑Testing Experimental Therapies
The Enemy isn't Big Pharma. It's the FDA and Regulators who won't allow you to test experimental therapies on yourself (or your dog). Even if it's life or death.
Engineering Smarter, Healthier Babies Through Embryo Selection
The man engineering smarter, healthier babies before they're born: Jonathan Anomaly. This philosopher-turned-biotech founder says the future of your child's health starts at the embryo. Here are 9 things you need to know about embryo selection: https://t.co/XVQF5le4bE
Turning Personal Loss Into Open Cancer Vaccine Platform
Paul's story developing a cancer vaccine for Rosie inspired me. I'm going to build something so that EVERYONE can do the same thing. My dog Lady died of hemagiosarcoma and I wish I'd been able to save her too ETA - hopefully a...
Drug Patents: Near-Term Generic Threat, Mid-Term Safeguards, Tirzepat
AI: Short-Term Cliffs (0-3 years remaining): Drugs like sacubitril/valsartan, dapagliflozin, pembrolizumab, ocrelizumab, daratumumab, and apixaban face imminent generic/biosimilar pressure Mid-Term Protection (4-7 years): Risankizumab and dupilumab have solid runway, supported by ongoing label expansions. Long-Term (8+ years): Tirzepatide's robust patents position it...
First Human Age‑Reversal Trial Targets Whole‑Body Reset
The first human age-reversal trial is officially happening. But before the FDA cleared it, Harvard professor David Sinclair had to pull off a mice experiment most scientists thought was impossible: "These mice had their optic nerve regenerated. We were able to...
Vaccination Boosts Survival in Multiple Myeloma Patients
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx https://t.co/L7r9caCcGN
Navigating Myeloma MRD: Risks, Benefits, and Treatment Decisions
MT @hhashmi87 #IMS25 Great Meet The Expert talk by @bdermanmd on MRD in Myeloma Risk vs benefit Who can stop treatment Active surveillance post discontinuation #mmMRD #mmsm https://t.co/YOBOPs7hQL
MRD‑Negative Patients May Stop Myeloma Maintenance Therapy
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP) - @bdermanmd et al. @ajjakubowiak #ASCO24 Abstract 106 https://t.co/FBTY7SnCxK #NCT04108624 #mmsm #mmMRD
ODAC Backs MRD as Early Endpoint for Myeloma Approvals
A Historic Turning Point: ODAC Unanimously Votes [4/12/24] in Favor of MRD Testing as an Early Endpoint in Myeloma Clinical Trials to Support Accelerated Approvals of New Treatments [Apr 18, 2024] @IMFmyeloma https://t.co/eDOgIrpVeR #mmMRD #mmsm #ctsm @FDAOncology https://t.co/W3vwHRTzhE
Clinicians Show Mixed Adoption of MRD in Myeloma
Clinician attitudes and practices toward measurable residual disease in multiple myeloma [Jun 7, 2020] @bdermanmd @jagoda_jasielec @ajjakubowiak Brit J Haematol https://t.co/8zhxYfYwZQ #mmsm #mmMRD https://t.co/QTlR2gv5Q0
Understanding MRD's Role in Multiple Myeloma Management
#mmMRD healthcare social media hashtag [Nov 21, 2020] Minimal/measurable residual disease (MRD) in multiple myeloma. Submitted by @bdermanmd to @symplur @healthhashtags https://t.co/grkkiox2yh #mmsm No longer available at Symplur https://t.co/IGDrNALHBP
China Biotech Receives FDA Approval for First Cell Therapy Trial
With FDA go ahead, a China #biotech notches a first in cell therapy testing https://t.co/QorwJmou8w by @realJacobBell $XENE $BHVN
Cancer Vaccines Show Promise for Hard-to-Treat Tumors
Cancer vaccines are showing marked efficacy vs refractory cancers and are going to be part of the future Rx armamentarium. Beyond that, ultimately, for prevention in high-risk individuals. A new stellar review @NatureMedicine https://t.co/PhtdZDtSBl https://t.co/okmwCD8AyB
Amyloid Antibody Therapy Triggers 100 Microhemorrhages in APOE4 Patient
100 brain microhemorrhages in a patient with cerebral amyloid angiopathy and 2 copies of APOE4 after amyloid antibody therapy https://t.co/ASpVuijFNW https://t.co/hdtwtv1usq
LAG‑3 Checkpoint Suffers Another Trial Setback, Focus Shifts
NEW: Another failure in the clinic in the world of LAG-3, a target once seen as possibly the next major checkpoint inhibitor after PD-1 and CTLA-4. My latest on Immutep's Phase 3 disappointment, as LAG-3 focus now shifts to a...
De Novo Enzymes Redefine Peptide Therapeutic Production
Peptide therapeutics are powerful. But making them has always been difficult. Traditional chemical synthesis can involve long routes, poor selectivity, and significant environmental impact, while biological production is often limited by the pathways evolution happened to provide. What if we could design...